# Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis

> **NCT04562389** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Karyopharm Therapeutics Inc** · enrollment: 353 (actual)

## Conditions studied

- Myelofibrosis

## Interventions

- **DRUG:** Selinexor
- **DRUG:** Selinexor
- **OTHER:** Placebo
- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT04562389
- **Lead sponsor:** Karyopharm Therapeutics Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-03-11
- **Primary completion:** 2026-02-20
- **Final completion:** 2028-03
- **Target enrollment:** 353 (ACTUAL)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04562389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04562389, "Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04562389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*